Combination of voriconazole and anidulafungin for treatment of triazole-resistant Aspergillus fumigatus in an In Vitro model of invasive pulmonary aspergillosis

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 10, 2012, Pages 5180-5185

  Jeans, Adam R ^a   Howard, Susan J ^a   Al Nakeeb, Zaid ^a   Goodwin, Joanne ^a   Gregson, Lea ^a   Warn, Peter A ^a   Hope, William W ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANIDULAFUNGIN; GALACTOMANNAN; TRIAZOLE; VORICONAZOLE;

ANTIFUNGAL RESISTANCE; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; ASPERGILLUS FUMIGATUS; CONTROLLED STUDY; DRUG EXPOSURE; FUNGUS GROWTH; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; LUNG ASPERGILLOSIS; NONHUMAN; PRIORITY JOURNAL;

ANTIFUNGAL AGENTS; ASPERGILLUS FUMIGATUS; CELL LINE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG INTERACTIONS; ECHINOCANDINS; HUMANS; INVASIVE PULMONARY ASPERGILLOSIS; MICROBIAL SENSITIVITY TESTS; MODELS, THEORETICAL; PULMONARY ALVEOLI; PYRIMIDINES; TRIAZOLES;

EID: 84866336137     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01111-12     Document Type: Article

References (47)

1. Arikan S, Lozano-Chiu M, Paetznick V, Rex JH. 2001. In vitro susceptibility testing methods for caspofungin against Aspergillus and Fusarium isolates. Antimicrob. Agents Chemother. 45:327-330. (Pubitemid 32039139)
2. Boutboul F, et al. 2002. Invasive aspergillosis in allogeneic stem cell transplant recipients: increasing antigenemia is associated with progressive disease. Clin. Infect. Dis. 34:939-943. (Pubitemid 34229762)
3. Bowman JC, et al. 2002. The antifungal echinocandin caspofungin acetate kills growing cells of Aspergillus fumigatus in vitro. Antimicrob. Agents Chemother. 46:3001-3012.
4. Chandrasekar PH, Cutright JL, Manavathu EK. 2004. Efficacy of voriconazole plus amphotericin B or micafungin in a guinea-pig model of invasive pulmonary aspergillosis. Clin. Microbiol. Infect. 10:925-928. (Pubitemid 39405842)
5. Clinical Laboratory Sciences Institute. 2008. Reference method for dilution antifungal susceptibility testing of filamentous fungi; approved standard, 2nd ed, M38-A2. Clinical and Laboratory Standards Institute, Wayne, PA.
6. Cuenca-Estrella M, et al. 2005. Combined activity in vitro of caspofungin, amphotericin B, and azole agents against itraconazole-resistant clinical isolates of Aspergillus fumigatus. Antimicrob. Agents Chemother. 49: 1232-1235. (Pubitemid 40327758)
7. Dannaoui E, Lortholary O, Dromer F. 2004. In vitro evaluation of double and triple combinations of antifungal drugs against Aspergillus fumigatus and Aspergillus terreus. Antimicrob. Agents Chemother. 48: 970-978. (Pubitemid 38280351)
8. Denning DW, Hope WW. 2010. Therapy for fungal diseases: opportunities and priorities. Trends Microbiol. 18:195-204.
9. European Committee for Antimicrobial Susceptibility Testing. 2008. EUCAST technical note on the method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for conidia-forming moulds. Clin. Microbiol. Infect. 14:982-984.
10. Greco WR, Bravo G, Parsons JC. 1995. The search for synergy: a critical review from a response surface perspective. Pharmacol. Rev. 47:331-385.
11. Herbrecht R, et al. 2002. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N. Engl. J. Med. 347:408-415. (Pubitemid 34851833)
12. Herbrecht R, et al. 2010. Caspofungin first-line therapy for invasive aspergillosis in allogeneic hematopoietic stem cell transplant patients: a European Organisation for Research and Treatment of Cancer study. Bone Marrow Transplant. 45:1227-1233.
13. Hope WW. 2012. Population pharmacokinetics of voriconazole in adults. Antimicrob. Agents Chemother. 56:526-531.
14. Hope WW, et al. 2007. Pathogenesis of Aspergillus fumigatus and the kinetics of galactomannan in an in vitro model of early invasive pulmonary aspergillosis: implications for antifungal therapy. J. Infect. Dis. 195: 455-466. (Pubitemid 46146125)
15. Hope WW, Shoham S, Walsh TJ. 2007. The pharmacology and clinical use of caspofungin. Expert Opin. Drug Metab. Toxicol. 3:263-274. (Pubitemid 47316041)
16. Hope WW, et al. 2005. Surface response modeling to examine the combination of amphotericin B deoxycholate and 5-fluorocytosine for treatment of invasive candidiasis. J. Infect. Dis. 192:673-680. (Pubitemid 41099317)
17. Howard SJ, et al. 2009. Frequency and evolution of azole resistance in Aspergillus fumigatus associated with treatment failure. Emerg. Infect. Dis. 15:1068-1076.
18. Howard SJ, et al. 2011. Pharmacokinetics and pharmacodynamics of posaconazole for invasive pulmonary aspergillosis: clinical implications for antifungal therapy. J. Infect. Dis. 203:1324-1332.
19. Jeans AR, et al. 2012. Pharmacodynamics of voriconazole in a dynamic in vitro model of invasive pulmonary aspergillosis: implications for in vitro susceptibility breakpoints. J. Infect. Dis. 206:442-452.
20. Kirkpatrick WR, Perea S, Coco BJ, Patterson TF. 2002. Efficacy of caspofungin alone and in combination with voriconazole in a Guinea pig model of invasive aspergillosis. Antimicrob. Agents Chemother. 46:2564-2568. (Pubitemid 34793464)
21. Klont RR, et al. 2006. Paradoxical increase in circulating Aspergillus antigen during treatment with caspofungin in a patient with pulmonary aspergillosis. Clin. Infect. Dis. 43:e23-e25. doi:10.1086/505603.
22. Koo S, Bryar JM, Baden LR, Marty FM. 2010. Prognostic features of galactomannan antigenemia in galactomannan-positive invasive aspergillosis. J. Clin. Microbiol. 48:1255-1260.
23. Kurtz MB, et al. 1994. Morphological effects of lipopeptides against Aspergillus fumigatus correlate with activities against (1,3)-beta-D-glucan synthase. Antimicrob. Agents Chemother. 38:1480-1489. (Pubitemid 24203556)
24. Lestner JM, et al. 2010. Pharmacokinetics and pharmacodynamics of amphotericin B deoxycholate, liposomal amphotericin B, and amphotericin B lipid complex in an in vitro model of invasive pulmonary aspergillosis. Antimicrob. Agents Chemother. 54:3432-3441.
25. MacCallum DM, Whyte JA, Odds FC. 2005. Efficacy of caspofungin and voriconazole combinations in experimental aspergillosis. Antimicrob. Agents Chemother. 49:3697-3701. (Pubitemid 41233020)
26. Maertens J, et al. 2009. Galactomannan serves as a surrogate endpoint for outcome of pulmonary invasive aspergillosis in neutropenic hematology patients. Cancer 115:355-362.
27. Maertens J, et al. 2006. Multicenter, noncomparative study of caspofungin in combination with other antifungals as salvage therapy in adults with invasive aspergillosis. Cancer 107:2888-2897. (Pubitemid 44937044)
28. Manavathu EK, Alangaden GJ, Chandrasekar PH. 2003. Differential activity of triazoles in two-drug combinations with the echinocandin caspofungin against Aspergillus fumigatus. J. Antimicrob. Chemother. 51: 1423-1425. (Pubitemid 36748933)
29. Marr KA, Boeckh M, Carter RA, Kim HW, Corey L. 2004. Combination antifungal therapy for invasive aspergillosis. Clin. Infect. Dis. 39:797-802. (Pubitemid 39244292)
30. Marr KA, et al. 2012. A randomised, double-blind study of combination antifungal therapy with voriconazole and anidulafungin versus voriconazole monotherapy for primary treatment of invasive aspergillosis, abstr LB 2812. Abstr. 22nd Eur. Congr. Clin. Microbiol. Infect. Dis.
31. Miceli MH, Anaissie EJ. 2007. When a paradoxical increase in serum galactomannan antigen during caspofungin therapy is not paradoxical after all. Clin. Infect. Dis. 44:757-760. (Author's reply, 44:760-761.)
32. Miceli MH, et al. 2008. Strong correlation between serum aspergillus galactomannan index and outcome of aspergillosis in patients with hematological cancer: clinical and research implications. Clin. Infect. Dis. 46: 1412-1422. (Pubitemid 351589942)
33. Nouer SA, et al. 2011. Earlier response assessment in invasive aspergillosis based on the kinetics of serum Aspergillus galactomannan: proposal for a new definition. Clin. Infect. Dis. 53:671-676.
34. O'Shaughnessy EM, Meletiadis J, Stergiopoulou T, Demchok JP, Walsh TJ. 2006. Antifungal interactions within the triple combination of amphotericin B, caspofungin and voriconazole against Aspergillus species. J. Antimicrob. Chemother. 58:1168-1176. (Pubitemid 44884135)
35. Perea S, et al. 2002. In vitro interaction of caspofungin acetate with voriconazole against clinical isolates of Aspergillus spp. Antimicrob. Agents Chemother. 46:3039-3041.
36. Perkhofer S, Jost D, Dierich MP, Lass-Flörl C. 2008. Susceptibility testing of anidulafungin and voriconazole alone and in combination against conidia and hyphae of Aspergillus spp. under hypoxic conditions. Antimicrob. Agents Chemother. 52:1873-1875. (Pubitemid 351614693)
37. Petraitiene R, et al. 2002. Antifungal efficacy of caspofungin (MK-0991) in experimental pulmonary aspergillosis in persistently neutropenic rabbits: pharmacokinetics, drug disposition, and relationship to galactomannan antigenemia. Antimicrob. Agents Chemother. 46:12-23. (Pubitemid 34031596)
38. Petraitis V, et al. 2009. Combination therapy in treatment of experimental pulmonary aspergillosis: in vitro and in vivo correlations of the concentration- and dose-dependent interactions between anidulafungin and voriconazole by Bliss independence drug interaction analysis. Antimicrob. Agents Chemother. 53:2382-2391.
39. Petraitis V, et al. 2003. Combination therapy in treatment of experimental pulmonary aspergillosis: synergistic interaction between an antifungal triazole and an echinocandin. J. Infect. Dis. 187:1834-1843. (Pubitemid 36724481)
40. Philip A, et al. 2005. In vitro synergy testing of anidulafungin with itraconazole, voriconazole, and amphotericin B against Aspergillus spp. and Fusarium spp. Antimicrob. Agents Chemother. 49:3572-3574. (Pubitemid 41060623)
41. Singh N, et al. 2006. Combination of voriconazole and caspofungin as primary therapy for invasive aspergillosis in solid organ transplant recipients: a prospective, multicenter, observational study. Transplantation 81: 320-326. (Pubitemid 43255714)
42. Snelders E, et al. 2008. Emergence of azole resistance in Aspergillus fumigatus and spread of a single resistance mechanism. PLoS Med. 5:e219. doi:10.1371/journal.pmed.0050219.
43. Troke PF, Hockey HP, Hope WW. 2011. Observational study of the clinical efficacy of voriconazole and its relationship to plasma concentrations in patients. Antimicrob. Agents Chemother. 55:4782-4788.
44. van de Sande WW, et al. 2009. Combination therapy of advanced invasive pulmonary aspergillosis in transiently neutropenic rats using human pharmacokinetic equivalent doses of voriconazole and anidulafungin. Antimicrob. Agents Chemother. 53:2005-2013.
45. Viscoli C, et al. 2009. An EORTC Phase II study of caspofungin as first-line therapy of invasive aspergillosis in haematological patients. J. Antimicrob. Chemother. 64:1274-1281.
46. Walsh TJ, et al. 2008. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin. Infect. Dis. 46: 327-360. (Pubitemid 351265310)
47. Wasylnka JA, Moore MM. 2002. Uptake of Aspergillus fumigatus conidia by phagocytic and nonphagocytic cells in vitro: quantitation using strains expressing green fluorescent protein. Infect. Immun. 70:3156-3163. (Pubitemid 34564179)